Replimune (NASDAQ: REPL) shares updated RP1, RP2 data deck for investors

Rhea-AI Filing Summary

Replimune Group, Inc. reported that it has released an updated corporate presentation covering recent business and strategic developments and clinical data for its RP1 and RP2 programs. The company plans to use this presentation in meetings with analysts, investors and others, including at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The slide deck is furnished as Exhibit 99.1, and a replay of the J.P. Morgan presentation webcast will be available on the company’s website under “Investors and Media” for 30 days. This information is furnished under Item 7.01 and is not deemed filed or incorporated by reference into other filings unless specifically stated.

false 0001737953 0001737953 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 12, 2026

REPLIMUNE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38596		82-2082553
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

500 Unicorn Park Drive

Suite 303

Woburn, MA 01801

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (781) 222-9600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		REPL		The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, Replimune Group, Inc. (the “Company”) released an updated corporate presentation reflecting certain recent business and strategic developments and clinical data in respect of its RP1 and RP2 programs. The Company intends to present information contained in the presentation in meetings with analysts, investors and others from time to time, including at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A copy of the presentation slides are furnished as Exhibit 99.1 to this Current Report on Form 8-K and a replay of the webcast of the J.P. Morgan presentation will be available on the Company’s website at www.replimune.com under “Investors and Media” for 30 days following the event. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.

The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Company Presentation dated January 14, 2026
104		Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REPLIMUNE GROUP, INC.
Date: January 12, 2026	By:	/s/ Sushil Patel
		Sushil Patel
		Chief Executive Officer

FAQ

What did Replimune Group, Inc. (REPL) disclose in this Form 8-K?

Replimune Group, Inc. disclosed that it has released an updated corporate presentation that reflects recent business and strategic developments and clinical data related to its RP1 and RP2 programs. The presentation is intended for use in meetings with analysts, investors and others.

Which programs are highlighted in Replimune’s updated corporate presentation?

The updated corporate presentation highlights recent clinical data and developments for Replimune’s RP1 and RP2 programs.

How can investors access Replimune’s new corporate presentation and related materials?

The presentation slides are furnished as Exhibit 99.1, and a replay of the J.P. Morgan Healthcare Conference presentation will be available on Replimune’s website at www.replimune.com under “Investors and Media” for 30 days following the event.

At which event will Replimune present the updated RP1 and RP2 information?

Replimune intends to present the updated information at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Is the information in Replimune’s updated presentation considered filed with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, and is not subject to Section 18 of the Securities Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor is it incorporated into other filings unless specifically referenced.

Who signed the Replimune Form 8-K related to the updated presentation?

The Form 8-K was signed on behalf of Replimune Group, Inc. by Sushil Patel, Chief Executive Officer.